268 related articles for article (PubMed ID: 10873872)
1. Anatomic and metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease.
Grampsas SA; Chandhoke PS; Fan J; Glass MA; Townsend R; Johnson AM; Gabow P
Am J Kidney Dis; 2000 Jul; 36(1):53-7. PubMed ID: 10873872
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients.
Nishiura JL; Neves RF; Eloi SR; Cintra SM; Ajzen SA; Heilberg IP
Clin J Am Soc Nephrol; 2009 Apr; 4(4):838-44. PubMed ID: 19339428
[TBL] [Abstract][Full Text] [Related]
3. Renal stone disease in autosomal dominant polycystic kidney disease.
Torres VE; Wilson DM; Hattery RR; Segura JW
Am J Kidney Dis; 1993 Oct; 22(4):513-9. PubMed ID: 8213789
[TBL] [Abstract][Full Text] [Related]
4. Assessment of metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease: a cross-sectional study.
Chasan O; Mirioglu S; Artan AS; Gursu M; Kazancioglu R; Elcioglu OC
Clin Exp Nephrol; 2023 Nov; 27(11):912-918. PubMed ID: 37493903
[TBL] [Abstract][Full Text] [Related]
5. Calcified renal stones and cyst calcifications in autosomal dominant polycystic kidney disease: clinical and CT study in 84 patients.
Levine E; Grantham JJ
AJR Am J Roentgenol; 1992 Jul; 159(1):77-81. PubMed ID: 1609726
[TBL] [Abstract][Full Text] [Related]
6. Contributory metabolic factors in the development of nephrolithiasis in patients with medullary sponge kidney.
Yagisawa T; Kobayashi C; Hayashi T; Yoshida A; Toma H
Am J Kidney Dis; 2001 Jun; 37(6):1140-3. PubMed ID: 11382681
[TBL] [Abstract][Full Text] [Related]
7. Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan.
Bargagli M; Dhayat NA; Anderegg M; Semmo M; Huynh-Do U; Vogt B; Ferraro PM; Fuster DG
Clin J Am Soc Nephrol; 2020 Jul; 15(7):1007-1014. PubMed ID: 32527945
[TBL] [Abstract][Full Text] [Related]
8. Body size and 24-hour urine composition.
Taylor EN; Curhan GC
Am J Kidney Dis; 2006 Dec; 48(6):905-15. PubMed ID: 17162145
[TBL] [Abstract][Full Text] [Related]
9. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.
Chapman AB; Guay-Woodford LM; Grantham JJ; Torres VE; Bae KT; Baumgarten DA; Kenney PJ; King BF; Glockner JF; Wetzel LH; Brummer ME; O'Neill WC; Robbin ML; Bennett WM; Klahr S; Hirschman GH; Kimmel PL; Thompson PA; Miller JP;
Kidney Int; 2003 Sep; 64(3):1035-45. PubMed ID: 12911554
[TBL] [Abstract][Full Text] [Related]
10. Determination of urinary lithogenic parameters in murine models orthologous to autosomal dominant polycystic kidney disease.
Ferraz RR; Fonseca JM; Germino GG; Onuchic LF; Heilberg IP
Urolithiasis; 2014 Aug; 42(4):301-7. PubMed ID: 24817661
[TBL] [Abstract][Full Text] [Related]
11. Volumetric determination of progression in autosomal dominant polycystic kidney disease by computed tomography.
Sise C; Kusaka M; Wetzel LH; Winklhofer F; Cowley BD; Cook LT; Gordon M; Grantham JJ
Kidney Int; 2000 Dec; 58(6):2492-501. PubMed ID: 11115083
[TBL] [Abstract][Full Text] [Related]
12. Association of kidney and cysts dimensions with anthropometric and biochemical parameters in patients with ADPKD.
Pietrzak-Nowacka M; Safranow K; Palacz J; Gołembiewska E; Marchelek-Myśliwiec M; Ciechanowski K
Ren Fail; 2015 Jun; 37(5):798-803. PubMed ID: 25869055
[TBL] [Abstract][Full Text] [Related]
13. Extracorporeal shockwave lithotripsy for urinary calculi in autosomal dominant polycystic kidney disease.
Delakas D; Daskalopoulos G; Cranidis A
J Endourol; 1997 Jun; 11(3):167-70. PubMed ID: 9181443
[TBL] [Abstract][Full Text] [Related]
14. Laparoscopic cyst decortication in autosomal dominant polycystic kidney disease: impact on pain, hypertension, and renal function.
Lee DI; Andreoni CR; Rehman J; Landman J; Ragab M; Yan Y; Chen C; Shindel A; Middleton W; Shalhav A; McDougall EM; Clayman RV
J Endourol; 2003 Aug; 17(6):345-54. PubMed ID: 12965058
[TBL] [Abstract][Full Text] [Related]
15. Autosomal dominant polycystic kidney disease.
Srivastava A; Patel N
Am Fam Physician; 2014 Sep; 90(5):303-7. PubMed ID: 25251090
[TBL] [Abstract][Full Text] [Related]
16. Experience with autosomal dominant polycystic kidney disease in patients before and after renal transplantation: a 7-year observation.
Sulikowski T; Tejchman K; Zietek Z; Rózański J; Domański L; Kamiński M; Sieńko J; Romanowski M; Nowacki M; Pabisiak K; Kaczmarczyk M; Ciechanowski K; Ciechanowicz A; Ostrowski M
Transplant Proc; 2009; 41(1):177-80. PubMed ID: 19249508
[TBL] [Abstract][Full Text] [Related]
17. Ovarian manifestations in women with autosomal dominant polycystic kidney disease.
Heinonen PK; Vuento M; Maunola M; Ala-Houhala I
Am J Kidney Dis; 2002 Sep; 40(3):504-7. PubMed ID: 12200801
[TBL] [Abstract][Full Text] [Related]
18. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
[TBL] [Abstract][Full Text] [Related]
19. Renal excretion of citrate in patients with chronic renal failure or nephrolithiasis.
Chen SM; Chung LC; Lee YH; Young TK
J Formos Med Assoc; 1991 Jan; 90(1):41-7. PubMed ID: 1679108
[TBL] [Abstract][Full Text] [Related]
20. Urinary citrate and renal stone disease: the preventive role of alkali citrate treatment.
Caudarella R; Vescini F
Arch Ital Urol Androl; 2009 Sep; 81(3):182-7. PubMed ID: 19911682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
